FXN and Friedreich ataxia: Because of the frataxin-dependent overexpression of ATR1R in FA mice undergoing neuroinflammatory challenge, this suggests that ATR1R antagonists may be a supplementary rational therapeutic strategy in FA in addition to PJ34-mediated PARP-1 suppression.